EIS 10700
Alternative Names: EIS-10700Latest Information Update: 10 Nov 2023
At a glance
- Originator Eisbach Bio
- Class Antivirals; Small molecules
- Mechanism of Action RNA helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 26 Apr 2023 Phase-I clinical trials in COVID-2019 infections (In volunteers) in Germany (PO)
- 26 Apr 2023 Eisbach Bio plans late stage clinical trials for COVID-2019 infections (PO)
- 24 Feb 2023 Eisbach Bio files a PCT patent application with WIPO for viral helicases inhibitors combination therapy with viral polymerase inhibitor worldwide